Skip to main content

Table 2 Comparative analysis between SoJIA children which were treated every 2 and every 4 weeks

From: Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

Parameters

Q2W (n =11)

Q4W (n =26)

р

Data of baseline

Hemoglobin, g/dl

9.8 (8.16; 11.6)

11,4 (10,8; 13,0)

0,006

Anemia, n (%)

9 (81.8)

12 (46,2)

0,07*

WBC, *109/l

17.2 (12.8; 20.8)

9,85 (7,8; 13,8)

0,008

WBC in 1 week, *109/l

11.6 (8.2; 19.0)

7.6 (5.2; 11.9)

0.05

Granulocytes, cells in 1 μl

13728 (10112; 18654)

6445 (4914; 8787)

0,002

Granulocytes in 1 week, cells 1 μl

8944 (6560; 15390)

3314 (1840; 7240)

0,005

Granulocytes in 2 weeks, cells 1 μl

8925 (7700; 10332)

3408 (2907; 3975)

0.01

CRP, mg/l

100.0 (20.6; 120.0)

18.0 (10.3; 74.5)

0.01

ESR, mm/h

46.0 (42.0; 63.0)

25.5 (12.0; 50.0)

0.01

Ferritin, mg/ml

1287.0 (326.0; 3509.0)

128.0 (51.0; 224.0)

0.0006

LDH, U/l

714.0 (635.0; 796.0)

464.0 (423.0; 513.0)

0.006

Total protein, g/dl

6.7 (6.2; 7.0)

7.2 (6.8; 7.8)

0.004

Albumin, g/dl

2.1 (1.8; 2.5)

3.1 (2.9; 3.3)

0.0003

Hepatomegaly

10 (90.9)

10 (38.5)

0.003

Splenomegaly

6 (54.6)

5 (19.2)

0.05

Lymphadenopathy

5 (45.5)

8 (30.8)

0.47

Coagulopathy

4 (36.3)

0 (0.0)

0.005*

Interstitial lung disease

5 (45.5)

1 (3.9)

0.005*

Heart involvement

6 (54.6)

4 (15,4)

0.04*

CNS dysfunction

6 (54.6)

0 (0.0)

0.0001*

MAS before TCZ (any time point)

7 (63.6)

5 (19.2)

0.018*

MAS immediately precede TCZ

5 (45.5)***

0 (0.0)

0.001*

Outcomes during TCZ course

Corticosteroids discontinuation, n (%)

2/7 (28.6)

19/19 (100.0)

0.0001*

Corticosteroids discontinuation, days

167.0 (94.0; 237.0)

62.0 (34.0; 93.0)

0.005

Methotrexate discontinuation, due to remission of SoJIA, n (%)

1/8 (12.5)

8/24 (33.3)

0.39*

Cyclosporine A discontinuation, n (%)

3/7 (42.9)

8/13 (61.5)

0.64*

SoJIA relapses

5 (45.5)

2 (7.7)

0.016*

MAS during TCZ

5 (45.5)***

0 (0.0)

0.001*

Inactive disease

0 (0.0)

12/25** (48.0)

0.03*

TCZ-off remission

0 (0.0)

7/25** (28.0)

0.15*

  1. *Fisher’s exact test, **the data analysis was performed on 25 patients (1 withdrew due to infusion reaction), ***the same patients whom TCZ was initiated during the MAS (MAS before TCZ and after)
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096